Millions of men are losing their hair and their confidence. Two new drugs promise a genuine breakthrough. But will they arrive in time?
By Sarwar Kawoosa
New Delhi: Nikhil, 22, does not recognise the man in the mirror anymore. Every morning, he tilts his head towards the bathroom light. He parts his hair. He watches. The hairline that once sat proudly across his forehead has retreated. The temples are bare. At the crown, a thin patch spreads a little more each week. Eighteen months ago, Nikil had thick, black curls. Today, he mostly sees skin.
“I used to love swimming. Now I cannot enter a pool,” he says. “I flinch when someone reaches for my cap. I quit cricket. I am 22, but I feel like I am losing my twenties.”
Nikhil is not alone. Male pattern baldness, clinically known as androgenetic alopecia, affects a staggering number of men, yet society continues to treat it as a vanity issue rather than a genuine mental health concern. Globally, 25 percent of men begin losing hair before the age of 21. By 35, that figure climbs to 66 percent. In India, the situation is particularly alarming. Recent data suggests that over 50 percent of Indian men experiencing hair loss are under the age of 25.
The global hair loss industry is worth an estimated 8 to 10 billion dollars, yet much of that wealth is built on false hope. Since the 1950s, a new “cure for baldness” headline has emerged every few years. One Japanese scientist even released a music CD claiming it could regrow hair simply by listening to it. The pattern is always the same: a sensational claim, a surge of excitement, and then silence. Existing treatments offer only partial relief. Minoxidil improves hair density modestly but does not restore lost hair. Finasteride works for roughly 80 percent of men but requires lifelong use and carries risks of hormonal side effects. Hair transplants remain the closest thing to a permanent fix, but at 3 to 4 lakh rupees or more, they are out of reach for most Indians. Nikhil has tried them all. Nothing has worked.
But now, for the first time in nearly three decades, there is genuine reason for hope. Two new drugs are generating serious excitement in the scientific community.
The first, Clascoterone, is being developed by Ireland based Cassiopea Pharmaceuticals. Unlike finasteride, which reduces DHT across the entire body and can disrupt hormonal balance, Clascoterone targets DHT receptors locally, right at the hair follicle. The result is a treatment with no systemic side effects. No hormonal disruption. No sexual dysfunction. The company has already released its Phase 3 trial results, which show significant improvement in hair count with minimal adverse effects.
The second, known as PP405, may be even more remarkable. Researchers at UCLA discovered a molecule capable of reactivating dormant hair follicle stem cells. For decades, scientists assumed that once a follicle stopped producing visible hair, it was dead. But those follicles are not dead. They are sleeping. PP405 wakes them up. In Phase 2 human trials released in mid 2025, 31 percent of participants showed a greater than 20 percent increase in hair density in just eight weeks, while the placebo group showed no improvement whatsoever. “It is a completely different pathway and mechanism,” one researcher involved in the study said. “We are not slowing down hair loss. We are reversing it. That has never been done before.”
Here is the catch. Even if both drugs continue to perform as hoped, the journey from clinical trial to your local chemist is a long one. After clearing human trials, both drugs will need approval from the US FDA. For them to reach Indian pharmacies, they must additionally clear the CDSCO, India’s drug regulatory body, which requires bridging trials to confirm the drug works on Indian genetics. Experts estimate that Clascoterone will reach the Indian market no earlier than 2028 or 2029. PP405, still in earlier trials, is unlikely to arrive before 2029 or 2030, and that is being optimistic. For someone like Nikhil, already at Stage 3 on the Norwood scale, his window may close before the drugs even arrive. “The earlier you catch hair loss, the more follicles remain dormant rather than permanently miniaturised,” explains Dr. Anjali Mehta, a Mumbai based dermatologist. “A 22 year old waiting until 2029 could still benefit. But a 30 year old with advanced hair loss may have missed the window.”
Even when the drugs do arrive, cost remains a formidable barrier. Pharmaceutical companies hold patent monopolies on new drugs, allowing them to set prices as high as the market allows. A tactic called evergreening, filing minor modifications to extend patent protection, ensures these monopolies last as long as possible. However, India’s patent laws offer a rare shield. Section 3D of India’s Patents Act deliberately blocks patents on trivial modifications, effectively making evergreening much harder on Indian soil. Additionally, Indian generic manufacturers like Cipla, Sun Pharma, and Dr. Reddy’s can prepare their versions in advance and launch the moment a patent expires or a licensing deal is struck. Experts estimate that prices could eventually drop by up to 85 percent once generic competition floods the market. The system, experts say, is not piracy. It is policy. A deliberate strategy designed to make medicine accessible to a billion people who could never afford Western prices.
For Nikhil, and for the countless others playing this waiting game, the cure may come too late, or it may never come at all. Drug trials fail. Regulatory approvals stall. Companies fold. Which is why doctors and mental health professionals urge men dealing with hair loss to focus on what they can control, rather than chasing what they cannot. The men who seem to fare best are those who, at some point, choose to stop defining themselves by their hair and start defining themselves by everything else. Their physical health. Their career. Their relationships. Their character. As one young man who participated in our conversations put it: “I went through a phase where I did not want to talk about it. But now I have talked about it, and I do not think it is as important anymore.”
The science is real. The hope is justified. Clascoterone and PP405 represent the most credible advances in hair loss research in a generation. But the road ahead is long, the cost uncertain, and the timeline tight. For millions of men in India, the question is no longer just whether baldness will be cured. It is whether the cure will arrive in time, and whether they can afford it when it does. Until then, the most honest prescription may be the hardest one to swallow: acceptance. But for the first time in 25 years, acceptance is no longer the only option. The cure is coming. The question is whether it will find you in time.
